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Oral route is the simplest and easiest way of drug administration, because of the greater stability, lesser bulk, and cheap cost of 
production, accurate dosage and easy process, solid oral dosage forms have several advantages over other dosage forms. All the poor 
water soluble drugs after oral administrations are not well absorbed and thus leads to decrease in inherent efficiency of drugs. 
Therefore, for oral drug delivery system the improvement of drug solubility thereby its oral bio-availability is the most important 
aspect of drug development process. Biperiden HCl is a potent drug (Maximum daily dose is 16mg/day), having extensive first pass 
metabolism resulting in poor Bioavailability. The pharmacokinetic profile of this drug showed 33±5 % Bioavailability and 18-24 
hours elimination half-life (t1/2). In the present study attempt has been made to prepare and characterize inclusion complex of 
Biperiden HCl with Hydroxypropyl β-Cyclodextrin. The inclusion complexes prepared by different methods i.e. Physical mixture, 
Kneading and Solvent evaporation methods. The prepared complexes were characterized using FT-IR. The inclusion complex 
prepared by Kneading method exhibited greatest enhancing in solubility and faster dissolution (93.98% drug release in 60 min) of 
Biperiden HCl. 
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INTRODUCTION 
Parkinson's disease (PD) is progressive, neurodegenerative 
disorder of the central nervous system, it is also known as 
idiopathic parkinsonism, hypokinetic rigid syndrome/HRS, 
or paralysis agitans. Death of dopamine-generating cells in 
the substantianigra (a region of the midbrain) is the main cause 
for motor symptoms of Parkinson's disease. The poor 
dissolution of relatively insoluble drugs like Biperiden HCl has 
a major pharmacokinetic problem in its absorption through oral 
dosage form and its extensive first pass metabolism resulting in 
poor Bioavailability.  
The three approaches in overcoming the bioavailability 
problems due to such causes are:  
 Pharmaceutical Approach – modification of formulation, 
manufacturing process or  physicochemical properties of 
drugs without changing the chemical structure 
 Pharmacokinetic Approach – pharmacokinetics of drugs is 
altered by modifying its chemical structure. 
 Biological Approach – route of drug administration may be 
changed such as changing from oral to parenteral route. 
 
In present study, Complexation of Biperiden HCl using 
Hydroxy propyl β-Cyclodextrin (HPβ-CD) has been used to 
modify its physicochemical properties. 
MATERIALS AND METHODS 
Biperiden HCl was obtained as gift sample from S.K 
Healthcare Pvt. Ltd, Hyderabad.  Hydoxypropyl β-
Cyclodextrin was obtained as gift sample from NU 
Therapeutics Pvt Ltd, Hyderabad. All other chemicals were of 
Analytical grade and procured from local market. 
 
PREPARATION OF INCLUSION COMPLEXES WITH 
HYDROXYPROPYL β-CYCLODEXTRIN:7 
1) Physical mixture: Biperiden HCl with HPβ-CD in different 
molar ratios (i.e. 1:1M, 1:2M) were mixed in a mortar for about 
one hour with constant trituration, passed through sieve No. 80 
and stored in a desiccators over fused calcium chloride. 
 
2) Kneading method: Biperiden HCl with HPβ-CD in different 
molar ratios (i.e. 1:1M, 1:2M) were taken. First cyclodextrin is 
added to the mortar, small quantity of 50 % ethanol is added 
while triturating to get slurry like consistency. Then slowly 
drug is incorporated into the slurry and trituration is further 
continued for one hour. Slurry is then air dried for 24 h, 
pulverized and passed through sieve No. 80 and stored in 
desiccators over fused calcium chloride. 
 
3) Solvent evaporation Method: Drug and HPβ-CD in different 
molar ratio are dissolved in a common solvent to get a clear 
solution. Mixed the both solutions than the clear solution was 
kept for stirring on a magnetic stirrer till all the solvent got 
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evaporated. The mass obtained was dried at 50°C and further 
sieved No. 80 or 100 sieve. Different variations used for 
preparation of inclusion complexes are shown in Table 1.  
 
Evaluation of HPβCD – Biperiden HCl Inclusion 
Complexes  
Drug Content Estimation
4: Inclusion complexes prepared by 
above methods were assayed for Bi-HCl content by dissolving 
a specific amount of the complexes (Drug Equivalent to 2mg) 
in methanol-Water system and analyzing for the Bi-HCl 
content spectrophotometrically at 258 nm on a 
spectrophotometer (Table 1). 
 
In-vitro release profile: In vitro release studies were carried 
out by conducting dissolution studies for pure drug and 
inclusion complexes. 500 ml of 0.1N HCl was used as 
dissolution medium and the study was carried out using USP II 
paddle type dissolution apparatus. Speed of rotation of the 
paddle was set at 50 rpm. Absorbance was measured at 258 nm 
using UV- Spectrophotometer (Table 2). 
 
Table 1: Biperiden HCl, Hydroxypropyl β-Cyclodextrin Complexes and its drug content  
Method Drug to Carrier Drug : Carrier  Batch Code % Drug content 
Physical Mixture Bi-HCL : HP β-CD 1:1 BPM1 99.05 
Bi-HCL : HP β-CD 1:2 BPM2 99.95 
Kneading Method Bi-HCL : HP β-CD 1:1 BKN1 105.35 
Bi-HCL : HP β-CD 1:2 BKN2 100.25 
Solvent evaporation 
method 
Bi-HCL : HP β-CD 1:1 BSE1 100.05 
Bi-HCL : HP β-CD 1:2 BSE2 100.5 
 
Table 2: Comparison of In-vitro dissolution data of all formulations 
Time 
(min) 
% Cumulative Drug Release 
PURE DRUG BPM1 BPM2 BKM1 BKM2 BSE1 BSE2 
0 0 0 0 0 0 0 0 
5 6.532 36.787 39.75164 42.16765 53.7648 39.14328 48.00836 
10 20.546 55.702 58.58979 58.89765 74.67490 56.76489 55.98548 
15 25.670 60.891 63.71974 76.65487 82.56387 72.87487 77.64870 
30 26.0274 62.262 78.86750 82.8764 85.98465 76.77498 79.60935 
45 27.79 74.460 81.54981 83.6954 90.88674 80.69804 82.92465 
60 28.634 79.650 83.66899 86.48768 93.98354 82.37658 87.89275 
 
The results of dissolution data fitted to Zero order and First 
order equation. The kinetic values obtained for different 
formulations are tabulated in Table. The linearity indicates that 
the release of drug from the complex is followed First order. 
 
CONCLUSION 
In the present work, studies were carried out on design, 
formulation development and evaluation of Biperiden HCl 
inclusion complex with a view to improve its aqueous 
solubility, dissolution rate and oral bioavailability. In-vitro 
dissolution studies for pure drug and inclusion complexes were 
carried out in 500 ml of 0.1N HCl using USP II paddle type 
dissolution apparatus. It is evident that the complex prepared 
was exhibited a faster dissolution when compared to pure drug 
dissolution data. A marked improvement in the dissolution 
rates observed with BKM2 prepared by Kneading method. The 
higher dissolution rates observed with inclusion complexes 
prepared by Kneading may be due to better interaction of drug 
Hydroxypropyl β- cyclodextrin. 
 
The inclusion complex of Biperiden HCl i.e.BKM2 complex 
was subjected to short-term stability studies by storing them at 
room temperature and at 400C and relative Humidity of 
75%RH. The samples were analysed at an interval of one week, 
three weeks and six weeks for their physical appearance, drug 
content values and dissolution profiles. No appreciable changes 
observed with the above parameters. 
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Figure 1:   Dissolution Rate Data Profile graph of Biperiden HCl and its complexes 
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